

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE  
Group Art Unit 1624

In Patent Application of

Niall Morrison Barr Martin, et al.

Application No. 10/021,506

Confirmation No.: 8516

Filed: October 30, 2001

Examiner: Richard L. Raymond

“PHTHALAZINONE DERIVATIVES”

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT  
PURSUANT TO 37 CFR §1.97(c) and (e)(2)

Mail Stop Amendment  
Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Sir:

The Examiner's attention is directed to the references which are listed on the attached Form PTO/SB/08A and copies of which are attached. Citation of these references is respectfully requested.

In accordance with 37 CFR 1.97(c) and (e)(2), the undersigned hereby certifies that no item of information contained in this information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application and, to the knowledge of the undersigned after making reasonable inquiry, was known to any individual designated in §1.56(c) more than three months prior to the filing of this statement.

No concession is made that these documents are prior art, and Applicant expressly reserves the right to antedate the documents as may be appropriate.

Respectfully submitted,

Wendy M. Seffrood  
Reg. No. 52,205


File No. 065435-9009  
Michael Best & Friedrich LLP  
One South Pinckney Street  
P. O. Box 1806  
Madison, WI 53701-1806  
(608) 257-3501

I, Diane J. Frauchiger, hereby certify that this correspondence is being deposited with the US Postal Service as first class mail in an envelope addressed to Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on the date of my signature.

Signature

December 7, 2004  
Date of Signature

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute of form 1449/PTO		<b>Complete if Known</b>	
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (use many sheets as necessary)		<b>Application Number</b>	10/021,506
		<b>Filing Date</b>	October 30, 2001
		<b>First Name Inventor</b>	Niall Morrison Barr Martin
		<b>Group Art Unit</b>	1624
		<b>Examiner Name</b>	Richard L. Raymond
		<b>Attorney Docket Number</b>	065435-9009
Sheet	1	of	1

**U.S. PATENT DOCUMENTS**

Examiner Initials	U.S. Patent Document Number	Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document

**FOREIGN PATENT DOCUMENTS**

Examiner Initials	Country Code	Foreign Patent Document Number	Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document	Translation	English Abstract
	PCT	WO/00/05219	Zambon Group S.P.A.	3 February 2000		
	IT	MI98A001671	Zambon Group S.P.A.	22 April 1999		

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer. Patent and Trademark Office, Washington, DC 0231.

DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box Alexandria, VA 22313-1450.



THE U.S. PATENT AND TRADEMARK OFFICE OFFICIAL MAILROOM STAMP AFFIXED HERETO  
ACKNOWLEDGES RECEIPT OF THE ITEMS CHECKED BELOW

Serial No.: 10/021,506


Applicant: NIAL MORRISON BARR MARTIN ET AL.

Mailing Date: 27 Sept. 2002

Title/Mark: PHTHALAZINONE DERIVATIVES

- ☐ Transmittal Letter (duplicate)  
☐ Patent Application ☐ Utility ☐ Provisional ☐ Design ☐ CIP ☐ Cont ☐ Div ☐ PCT  
☐ Continued Prosecution Application ☐ International Preliminary Report on Patentability  
☐ Trademark/Service Mark/Certification Mark Application ☐ Use ☐ Intent-to-Use  
☐ Declaration and Power of Attorney  
☐ Drawing(s) ☐ Formal ☐ Informal ☐ Specimens (3)  
☐ Verified Statement(s) Claiming Small Entity Status  
☐ Assignment/Recordation Form Cover Sheet: ☐ Patent ☐ Trademark  
☒ Information Disclosure Stmt/PTO-1449/Relevant  
☐ Power of Attorney ☐ PCT ☐ Amendment ☐ Preliminary ☐ After FINAL Rejection  
☐ Extension of Time (duplicate)  
☐ Transmittal of Payment of Issue Fee/Part B-Issue Fee Transmittal Form (PTOL-85B) (duplicate)  
☐ PCT Request (\_\_\_\_ sheets) and Fee Calculation Sheet  
☐ PCT Demand Ch. II (\_\_\_\_ sheets) and Fee Calculation Sheet

Michael Best & Friedman LLP  
RECEIVED  
OCT 10 2002  
DOCKETING  
MADISON, WI




File No.: 065435/9009 Atty: GJ Frenchick  
Cert. of Mailing: ☒ 37 CFR 1.8 ☐ 37 CFR 1.10 Express Mail ☐ Reg. No. 29,018

CPI



THE U.S. PATENT AND TRADEMARK OFFICE OFFICIAL MAILROOM STAMP AFFIXED HERETO  
ACKNOWLEDGES RECEIPT OF THE ITEMS CHECKED BELOW

Serial No.: 10/021506  
Applicant: Niall M.B. Martin et al  
Mailing Date: May 14, 2002  
Title/Mark: Phthalazimone Derivatives



- ☐ Transmittal Letter (duplicate)  
☐ Patent Application ☐ Utility ☐ Provisional ☐ Design ☐ CIP ☐ Cont ☐ Div ☐ PCT  
☐ Continued Prosecution Application ☐ Cont ☐ Use ☐ Intent-to-Use  
☐ Trademark ☐ Service Mark ☐ Certification Mark Application  
☐ Declaration and Power of Attorney  
☐ Drawing(s) ☐ Formal ☐ Informal ☐ Specimens (3)  
☐ Verified Statement(s) Claiming Small Entity Status  
☐ Assignment/Recordation Form Cover Sheet: ☐ Patent ☐ Trademark  
☒ Information Disclosure Stmt/PTO-1449/References ☒ Supplemental  
☐ Power of Attorney ☐ PCT ☐ Associate ☐ After FINAL Rejection ☐ Status Inquiry  
☐ Amendment ☐ Preliminary ☐ After FINAL Rejection  
☐ Extension of Time (duplicate)  
☐ Transmittal of Payment of Issue Fee/Part B-Issue Fee Transmittal (Form PTOL-85B) (duplicate)  
☐ PCT Request (\_\_\_\_ sheets) and Fee Calculation Sheet  
☐ PCT Demand Ch. II (\_\_\_\_ sheets) and Fee Calculation Sheet

JUN 18 2002

RECEIVED  
BUCKETING  
MADISON, WI

File No.: 065435-9009 Atty: Shady Greenchick  
Cert. of Mailing: ☒ 37 CFR 1.8 ☐ 37 CFR 1.10 Express Mail ☒ Reg. No. 29018

CPI




THE U.S. PATENT AND TRADEMARK OFFICE OFFICIAL MAILROOM STAMP AFFIXED HERETO  
ACKNOWLEDGES RECEIPT OF THE ITEMS CHECKED BELOW

Serial No.: 10/021,506

Applicant: MARTIN ET AL.

Mailing Date: 2.5.02

Title/Mark: PHTHALAZINONE DERIVATIVES



- ☒ Transmittal Letter (duplicate) ☐ Check: \$  
☐ Patent Application ☐ Utility ☐ Provisional ☐ Design ☐ Plant ☐ Cont ☐ Div ☐ PCT  
☐ Continued Prosecution Application ☐ Cont ☐ Div  
☐ Trademark/☐ Service Mark/☐ Certification Mark Application ☐ Use ☐ Intent-to-Use  
☐ Declaration and Power of Attorney  
☐ Drawing(s) ☐ Formal ☐ Informal ☐ Specimens (3)  
☐ Verified Statement(s) Claiming Small Entity Status  
☐ Assignment/Recordation Form Cover Sheet: ☐ Patent ☐ Trademark  
☒ Information Disclosure Stmt/PTO-1449/References ☐ Supplemental  
☐ Power of Attorney ☐ PCT ☐ Associate  
☐ Amendment ☐ Preliminary ☐ After-Final Rejection  
☐ Extension of Time (duplicate) ☐ Status Inquiry  
☐ Transmittal of Payment of Issue Fee/Part B-Issue Fee Transmittal (Form PTOL-85B) (duplicate)  
☐ PCT Request (\_\_\_\_ sheets) and Fee Calculation Sheet  
☐ PCT Demand Ch. II (\_\_\_\_ sheets) and Fee Calculation Sheet


Shapiro & Friedrich LLP  
RECEIVED  
MAR 4 2002

DOCKETING  
MADISON, WI

File No.: 065436/9009 Atty: GJFrenchick

Cert. of Mailing: ☒ 37 CFR 1.8 ☐ 37 CFR 1.10 Express Mail ☒ Reg. No. 29,018

CPI



FORM PTO-1449 U.S. DEPARTMENT OF COMMERCE  
PATENT AND TRADEMARK OFFICE

ATTY. DOCKET NO.: 065435/9009  
SERIAL NO.: 10/021,506  
APPLICANT: Martin *et al.*  
FILING DATE: October 30, 2001  
GROUP: Not yet assigned

INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT:

(Use several sheets if necessary)

### U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB CLASS	FILING DATE IF APPROPRIATE
	AA	5,032,617	Jul 16, 1991	Lee, <i>et al.</i>			
	AB	5,215,738	Jun 1, 1993	Lee, <i>et al.</i>			
	AC	5,041,653	Aug 20, 1991	Lee, <i>et al.</i>			
	AD	5,874,444	Feb 23, 1999	West			
	AE	3,813,384	May 28, 1974	Vogelsang, <i>et al.</i>			
	AF	5,556,856	Sep 17, 1996	Engel, <i>et al.</i>			
	AG	4,841,047	Jun 20, 1989	Engel, <i>et al.</i>			
	AH	4,665,181	May 12, 1987	Thomas, <i>et al.</i>			
	AI	6,197,785	Mar 6, 2001	Jackson, <i>et al.</i>			

### FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB CLASS	TRANSLATION YES NO
	AJ	WO 91/18591	Dec 12, 1991	PCT			
	AK	WO 00/67734	Nov 16, 2000	PCT			
	AL	EP 0 355 750	Feb 28, 1990	Europe			
	AM	WO 99/11649	Mar 11, 1999	PCT			
	AN	WO 99/11624	Mar 11, 1999	PCT			
	AO	EP 0 590 551	Apr 6, 1994	Europe			
	AP	WO 00/44726	Aug 3, 2000	PCT			X (claims)
	AQ	WO 99/44612	Sep 10, 1999	PCT			
	AR	EP 0 792 643	Sep 3, 1997	Europe			
	AS	WO 96/19225	Jun 27, 1996	PCT			
	AT	WO 99/11645	Mar 11, 1999	PCT			
	AU	WO 01/16137	Mar 8, 2001	PCT			
	AV	WO 99/08680	Feb 25, 1999	PCT			
	AW	WO 94/10151	May 11, 1994	PCT			

### OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

	AX	D'Amours <i>et al.</i> , 1999, <i>Biochem. J.</i> 342: 249-268
	AY	d'Adda di Fagagna <i>et al.</i> , 1999, <i>Nature Gen.</i> , 23(1): 76-80
	AZ	Althaus, F.R. and Richter, C., 1987, ADP-Ribosylation of Proteins: Enzymology and Biological Significance, Springer-Verlag, Berlin – <b>not being sent</b>

EXAMINER

DATE CONSIDERED

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

FORM PTO-1449 U.S. DEPARTMENT OF COMMERCE  
(Rev. 2-92) PATENT AND TRADEMARK OFFICE

ATTY. DOCKET NO.: 065435/9009  
SERIAL NO.: 10/021,506  
APPLICANT: Martin *et al.*  
FILING DATE: October 30, 2001  
GROUP: Not yet assigned



INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT:

(Use several sheets if necessary)

BA	Rhun <i>et al.</i> , 1998, <i>Biochem. Biophys. Res. Commun.</i> , 245: 1-10
BB	Miwa <i>et al.</i> , 1977, <i>Arch. Biochem. Biophys.</i> 181: 313-321
BC	Burzio <i>et al.</i> , 1975, <i>Proc. Soc. Exp. Biol. Med.</i> 149: 933-938
BD	Hirai <i>et al.</i> , 1983, <i>Cancer Res.</i> 43: 3441-3446
BE	Durkacz <i>et al.</i> , 1980, <i>Nature</i> 283: 593-596
BF	Berger, N.A., 1985, <i>Radiation Research</i> , 101: 4-14
BG	Ben-Hur <i>et al.</i> , 1984, <i>British Journal of Cancer</i> , 49 (Suppl. VI): 34-42
BH	Schlicker <i>et al.</i> , 1999, <i>Int. J. Radiat. Biol.</i> , 75: 91-100
BI	Wang <i>et al.</i> , 1995, <i>Genes Dev.</i> , 9: 509-520
BJ	Ménissier de Murcia <i>et al.</i> , 1997, <i>Proc. Natl. Acad. Sci. USA</i> , 94: 7303-7307
BK	Cantoni <i>et al.</i> , 1989, <i>Biochim. Biophys. Acta</i> , 1014: 1-7
BL	Szabo, <i>et al.</i> , 1997, <i>J. Clin. Invest.</i> , 100: 723-735
BM	Cosi <i>et al.</i> , 1994, <i>J. Neurosci. Res.</i> , 39: 38-46
BN	Said <i>et al.</i> , 1996, <i>Proc. Natl. Acad. Sci. U.S.A.</i> , 93: 4688-4692
BO	Liaudet <i>et al.</i> , 2000, <i>Proc. Natl. Acad. Sci. U.S.A.</i> , 97(3): 10203-10208
BP	Gäken <i>et al.</i> , 1996, <i>J. Virology</i> , 70(6): 3992-4000
BQ	Rattan and Clark, 1994, <i>Biochem. Biophys. Res. Comm.</i> , 201 (2): 665-672
BR	Berge <i>et al.</i> , 1977, "Pharmaceutically Acceptable Salts," <i>J. Pharm. Sci.</i> , Vol. 66, pp. 1-19. <u>Protective Groups in Organic Synthesis</u> (T. Green and P. Wuts, Wiley, 1991).
BS	Yamaguchi, <i>et al.</i> , <i>J. Med. Chem.</i> 1993, 36, 4052 – 4060 <u>Remington's Pharmaceutical Sciences</u> , 18th edition, Mack Publishing Company, Easton, Pa., 1990
BT	Skehan, P., <i>et al.</i> , 1990, <i>J. Natl. Cancer Inst.</i> , 82, 1107-1112
BU	Perkins <i>et al.</i> , <i>Cancer Research</i> , 61, 4175-4183 (2001)
BV	Chemical Abstracts 122:204573
BW	Chemical Abstracts 104:102050
BX	Chemical Abstracts 134:65983
BY	Chemical Abstracts 132:273943
BZ	Yamaguchi, <i>et al.</i> , <i>J. Med. Chem.</i> , 36, 4061-4068 & 4052-4060 (1993)
CA	Banasik, <i>et al.</i> , <i>J. Biol. Chem.</i> , 267, 1569-1575 (1992)
CB	Hall, Wong & Chapman, <i>Anti-Cancer Drugs</i> , Vol. 6 – 1995, pp 147-155 (relates to a Chem Abs)
CC	Bold, G., <i>et al.</i> , <i>J. Med. Chem.</i> , 2000, 43, 2310-2323
CD	UKPO Search Report
CE	Martin, N., <i>et al.</i> , Abstract 107, ADPR 2001 13 <sup>th</sup> International Symposium on ADP-ribosylation

EXAMINER

DATE CONSIDERED

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

FORM PTO-1449 U.S. DEPARTMENT OF COMMERCE  
(Rev. 2-92) PATENT AND TRADEMARK OFFICE

ATTY. DOCKET NO.: 065435/9009

SERIAL NO.: 10/021,506

INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT:

APPLICANT: Martin *et al.*

(Use several sheets if necessary)

FILING DATE: October 30, 2001

GROUP: Not yet assigned

### U.S. PATENT DOCUMENTS

EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUB CLASS	FILING DATE IF APPROPRIATE

### FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB CLASS	TRANSLATION YES NO
	CF	WO 98/43477	Oct. 8, 1998	PCT		

### OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

CG	El-Tamaty, <i>et al.</i> , "Sy[n]thesis and biological activity of some 4-benzyl-1(2H)-phthalazinone derivatives," <i>Chemical Abstracts</i> , 300924j, v. 125, No. 23 (1996)
CH	El-Tamaty, <i>et al.</i> , "Synthesis and biological activity of some 4-benzyl-1(2H)-phthalazinone derivatives," <i>Indian J. Chemistry</i> , v. 35B, pp. 1067-1072 (Oct. 1996)
CI	Shimizu, T., <i>et al.</i> , "Inhibitory effects of Azelastine and Tranilast on leukotriene C <sub>4</sub> generation by rat colonic mucosa," <i>Prostaglandins Leukotrienes and Essential Fatty Acids</i> , 53, 355-358(1995).

Q:\CLIENT\065435\9009\B0143513.1

EXAMINER

DATE CONSIDERED

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.



EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.